Phenytoin: A Comprehensive Review of Pharmacology, Pharmacokinetics, Therapeutic Applications, Adverse Effects, Drug Interactions and Pharmacogenomics
Year: 2026
Type: article
Abstract: Phenytoin is a well-established hydantoin derivative and an important antiseizure medication used primarily for the management of focal-onset seizures and generalized tonic-clonic seizures. It exerts its anticonvulsant activity mainly by blocking voltage-gated sodium channels and reducing repetitive neuronal firing, thereby limiting the spread of abnormal electrical activity in the brain. Phenytoin has been used clinically for several decades; however, its therapeutic application is associated with several pharmacokinetic and pharmacological challenges. The drug exhibits high plasma protein binding and nonlinear, dose-dependent pharmacokinetics because hepatic metabolism becomes saturated at therapeutic concentrations. Consequently, relatively small changes in dosage may produce significant changes in plasma drug concentrations, making therapeutic drug monitoring important in selected patients. This review provides a comprehensive overview of the chemistry, mechanism of action, pharmacological properties, pharmacokinetics, therapeutic applications, dosage forms, adverse drug reactions, drug interactions, contraindications, and therapeutic drug monitoring of phenytoin. Particular attention is given to its hepatic metabolism through cytochrome P450 enzymes, especially CYP2C9 and CYP2C19, and its ability to induce several drug-metabolizing enzymes, which can result in clinically significant drug interactions. Important adverse effects, including neurological effects, gingival hyperplasia, dermatological reactions, hepatotoxicity, and serious hypersensitivity reactions, are also discussed. The review further highlights the clinical significance of protein binding and altered albumin concentrations in interpreting phenytoin plasma levels. Recent developments in phenytoin therapy, including pharmacogenomics, individualized dosing, therapeutic drug monitoring, population pharmacokinetic approaches, and the role of HLA genetic variants in susceptibility to severe cutaneous adverse reactions, are also considered. Fosphenytoin, a water-soluble prodrug of phenytoin, is discussed with respect to its role in parenteral therapy and formulation advantages. Overall, understanding the pharmacological and pharmacokinetic characteristics of phenytoin is essential for optimizing its therapeutic efficacy while minimizing toxicity and drug-interaction risks. Advances in precision medicine and pharmacogenomic-guided therapy may contribute to safer and more individualized use of phenytoin in the future.
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Keywords: phenytoin, antiepileptic drugs, voltage-gated sodium channel blockade, pharmacokinetics, nonlinear pharmacokinetics, hepatic metabolism, CYP2C9, CYP2C19, drug interactions, adverse drug reactions, gingival hyperplasia, hepatotoxicity, hypersensitivity, therapeutic drug monitoring, protein binding, albumin, pharmacogenomics, fosphenytoin, focal seizures, generalized tonic-clonic seizures, individualized dosing, population pharmacokinetics, severe cutaneous adverse reactions
Open Access status: green
OpenAlex ID: W7229506247
